GlassScriptPhysician profile
Michelle L Cheever
NPI 1558308940
$1,905.09
in general payments reported to CMS, 2019-2025
20 companies · $804 in 2025
The $804 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.46 · 2022: $199 · 2023: $515 · 2024: $301 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $917.04 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $117.54 | 2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $101.43 | 2025 | |
| Lilly USA, LLC | $98.19 | 2022-2025 | Ebglyss, Mounjaro |
| Genzyme Corporation | $96.55 | 2023-2025 | |
| Abbvie INC. | $94.52 | 2021-2023 | |
| Exact Sciences Corporation | $88.82 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $87.53 | 2023-2025 | Cuvitru, Takhzyro, Trintellix |
| Sunovion Pharmaceuticals INC. | $45.42 | 2021 | |
| Hikma Pharmaceuticals USA | $40.56 | 2023 | Ryaltris |
| Novo Nordisk INC | $32.07 | 2022-2023 | Wegovy |
| Pfizer INC. | $27.06 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $26.07 | 2025 | Neffy |
| Optinose US, INC. | $25.21 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $23.25 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $23.11 | 2024 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $16.67 | 2025 | Airsupra |
| Abbott Laboratories | $15.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.04 | 2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Cheever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.